Last reviewed · How we verify
NCT06065605
Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease
trial in Fabry Disease in 40 participants. Status unknown.
12 July 2025
Quick facts
| Lead sponsor | Lysosomal and Rare Disorders Research and Treatment Center, Inc. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 14 September 2023 |
| Primary completion | 12 July 2025 |
| Estimated completion | 12 September 2025 |
| Sites | 2 locations across United States |
Conditions studied
- Fabry Disease — all drugs for Fabry Disease →
Sponsor
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Who can join
Adults 18 to 80, any sex, with Fabry Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research is to collect biological samples (urine) to develop assays for immune biomarkers to possibly in the future be able to screen subjects with Fabry disease and be able to understand better progression of nephropathy in Fabry disease and predict nephropathy in Fabry disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06065605
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Fabry Disease
Currently open trials in the same condition.
- NCT07187440 — A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease · recruiting
- NCT06776419 — the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease · recruiting
- NCT06539624 — Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease · NA · recruiting
- NCT07277361 — Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment · recruiting
- NCT06270316 — Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease · Phase 1, PHASE2 · recruiting
Other Lysosomal and Rare Disorders Research and Treatment Center, Inc. trials
Trials by the same sponsor.
- NCT06116071 — Biomarkers Related to Bone in Pediatric Gaucher Disease · unknown
- NCT04724083 — Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy · unknown
- NCT04055831 — Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06065605 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lysosomal and Rare Disorders Research and Treatment Center, Inc.
- Last refreshed: 4 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06065605.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing